Latest News

New Zealand has been identified as a 'major outlier' among comparable OECD countries, with the lowest level of public investment in medicines, according to a new report by the New Zealand Institute of Economic Research.

The latest round of hand-wringing in an ABC article about so-called 'pharma advertising' is less a public policy debate and more a case study of condescending ideas that should have been locked in a time capsule a very long time ago.

With more than 2,900 life sciences organisations employing one in every 60 Australians, the sector continues to grow as a pillar of the nation’s future innovation economy. This week’s announcements, from expanding trade facilitation to forging international partnerships and welcoming record global delegates, underscore Australia’s ambition to play a leading role in the global life sciences landscape.

A new report from the Queensland Futures Institute (QFI), supported by Novo Nordisk, outlines a prevention-first strategy aimed at tackling overweight and obesity as a core productivity and workforce resilience issue.

Omico has announced the appointment of Richard Vines as its new Chair, succeeding Paul Jeans, who is stepping down after five years of leadership that helped shape the organisation into a national leader in precision oncology.

Island Pharmaceuticals (ASX:ILA) has confirmed that the US Food and Drug Administration will provide formal feedback on its antiviral candidate Galidesivir by 12 November 202, despite recent government shutdowns in the United States.

Noxopharm (ASX:NOX) has secured a significant milestone in the development of its Sofra technology platform, announcing the granting of its first patent by the United States Patent and Trademark Office.

4DMedical (ASX:4DX) has taken a significant step in the commercial rollout of its flagship CT:VQ technology. It announced that Stanford University has become the first US Academic Medical Centre to adopt the platform under a commercial agreement, less than two months after receiving clearance from the US Food and Drug Administration.

ImpediMed (ASX:IPD) has signalled a sharper focus on sales execution and market expansion following a strong finish to the financial year 2025, underpinned by record contract value, growing reimbursement coverage in the US, and advancing opportunities in lymphoedema, body composition and heart failure.

Clarity Pharmaceuticals (ASX:CU6) has highlighted new clinical and commercial data supporting its proprietary copper-based theranostics platform, underscoring its potential to redefine imaging and therapy for prostate cancer.

Starpharma (ASX:SPL) has received an upfront payment of US$5.5 million (A$8.5 million) from Genentech, a member of the Roche Group, marking the formal commencement of their recently announced license agreement focused on developing dendrimer-drug conjugates for selected oncology targets.

PYC Therapeutics (ASX:PYC) has taken a significant step forward in its goal to deliver the first treatment for Autosomal Dominant Optic Atrophy, announcing the initiation of a global repeat-dose Phase 1b clinical study of its investigational RNA therapy, PYC-001.